OCUP
Income statement / Annual
Last year (2024), Ocuphire Pharma, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Ocuphire Pharma, Inc.'s net income was -$57.53 M.
See Ocuphire Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$19.05 M |
$39.85 M |
$589.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$28.00 M
|
$6.00 K
|
$4.00 K
|
$4.00 K
|
$8.00 K
|
$3.00 K
|
$48.21 K
|
$42.36 K
|
$32.92 K
|
$27.50 K
|
| Gross Profit |
-$28.00 M
|
$19.04 M
|
$39.85 M
|
$585.00 K
|
-$8.00 K
|
-$3.00 K
|
-$48.21 K
|
-$42.36 K
|
-$32.92 K
|
-$27.50 K
|
| Gross Profit Ratio |
0
|
1
|
1
|
0.99
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$26.85 M
|
$17.65 M
|
$14.36 M
|
$15.17 M
|
$6.65 M
|
$2.37 M
|
$13.11 M
|
$10.72 M
|
$10.09 M
|
$12.15 M
|
| General & Administrative Expenses |
$18.22 M
|
$11.96 M
|
$7.27 M
|
$8.12 M
|
$2.82 M
|
$1.82 M
|
$743.28 K
|
$6.64 M
|
$6.32 M
|
$6.12 M
|
| Selling & Marketing Expenses |
$0.00
|
-$6.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.64 M
|
-$42.36 K
|
-$32.92 K
|
-$27.50 K
|
| Selling, General & Administrative Expenses |
$18.22 M
|
$11.95 M
|
$7.27 M
|
$8.12 M
|
$2.82 M
|
$1.82 M
|
$7.38 M
|
$6.60 M
|
$6.29 M
|
$6.09 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$14.00 K
|
-$157.00 K
|
$9.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$45.07 M
|
$29.61 M
|
$21.62 M
|
$23.29 M
|
$9.47 M
|
$4.19 M
|
$20.49 M
|
$17.31 M
|
$16.38 M
|
$18.24 M
|
| Cost And Expenses |
$73.07 M
|
$29.61 M
|
$21.62 M
|
$23.29 M
|
$9.47 M
|
$4.19 M
|
$20.54 M
|
$17.35 M
|
$16.41 M
|
$18.26 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.85 M
|
$313.70 K
|
$254.34 K
|
$207.00 K
|
$118.57 K
|
$103.27 K
|
| Interest Expense |
$0.00
|
$1.33 M
|
$9.00 K
|
$2.00 K
|
$6.85 M
|
$1.41 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$6.00 K
|
$4.00 K
|
$4.00 K
|
$8.00 K
|
$3.00 K
|
$48.21 K
|
$42.36 K
|
$32.92 K
|
$27.50 K
|
| EBITDA |
-$62.07 M |
-$9.97 M |
$18.22 M |
-$56.69 M |
-$17.77 M |
-$4.19 M |
-$14.32 M |
-$25.25 M |
-$8.96 M |
-$14.36 M |
| EBITDA Ratio |
0
|
-0.52
|
0.46
|
-96.24
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-0.55
|
0.46
|
-38.55
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.54 M
|
$589.00 K
|
-$23.00 K
|
-$33.99 M
|
-$4.65 M
|
-$1.98 M
|
$6.17 M
|
-$7.94 M
|
$7.11 M
|
$3.88 M
|
| Income Before Tax |
-$57.53 M
|
-$9.97 M
|
$18.20 M
|
-$56.69 M
|
-$24.62 M
|
-$6.17 M
|
-$14.37 M
|
-$25.29 M
|
-$9.31 M
|
-$14.38 M
|
| Income Before Tax Ratio |
0
|
-0.52
|
0.46
|
-96.25
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$12.00 K
|
$315.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.00
|
$5.00
|
$2.00
|
| Net Income |
-$57.53 M
|
-$9.99 M
|
$17.89 M
|
-$56.53 M
|
-$31.48 M
|
-$7.51 M
|
-$14.37 M
|
-$25.29 M
|
-$9.31 M
|
-$14.38 M
|
| Net Income Ratio |
0
|
-0.52
|
0.45
|
-95.98
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.15 |
-0.46 |
0.9 |
-3.81 |
-6.75 |
-10.56 |
-20.95 |
-0.91 |
-0.0408 |
-0.0792 |
| EPS Diluted |
-2.15 |
-0.46 |
0.87 |
-3.81 |
-6.75 |
-10.56 |
-20.95 |
-0.91 |
-0.0408 |
-0.0792 |
| Weighted Average Shares Out |
$26.72 M
|
$21.59 M
|
$19.93 M
|
$14.85 M
|
$4.66 M
|
$711.21 K
|
$685.74 K
|
$27.92 M
|
$227.98 M
|
$181.54 M
|
| Weighted Average Shares Out Diluted |
$26.72 M
|
$21.59 M
|
$20.60 M
|
$14.85 M
|
$4.66 M
|
$711.21 K
|
$685.74 K
|
$27.92 M
|
$227.98 M
|
$181.54 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
